Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 8/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16587348 | 1.00 | BTN3A1 (0.49) | BTN3A1TSHRRECQLLMNAHDAC3 | |
| SCHEMBL16587345 | 1.00 | BTN3A1 (0.49) | BTN3A1TSHRRECQLLMNAHDAC3 | |
| SCHEMBL18801715 | 0.93 | BTN3A1 (0.57) | BTN3A1TSHRRECQLLMNAHDAC3 | |
| SCHEMBL16587339 | 0.93 | BTN3A1 (0.57) | BTN3A1TSHRRECQLLMNAHDAC3 | |
| SCHEMBL18802032 | 0.93 | BTN3A1 (0.57) | BTN3A1TSHRRECQLLMNAHDAC3 | |
| SCHEMBL16587330 | 0.93 | BTN3A1 (0.57) | BTN3A1TSHRRECQLLMNAHDAC3 | |
| SCHEMBL16587316 | 0.93 | BTN3A1 (0.57) | BTN3A1TSHRRECQLLMNAHDAC3 | |
| SCHEMBL16587329 | 0.93 | BTN3A1 (0.57) | BTN3A1TSHRRECQLLMNAHDAC3 | |
| SCHEMBL19189363 | 0.88 | BTN3A1 (0.48) | BTN3A1LMNAPRTN3 | |
| SCHEMBL16587342 | 0.86 | BTN3A1 (0.57) | BTN3A1LMNAMAPTPRTN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783567-B2 | Processes and intermediates for preparing anti-HIV agents | GILEAD SCIENCES, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160340379-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | GILEAD SCIENCES, INC. | 2016-11-24 | — | — | US | disclosed |
| US-8987437-B2 | Processes and intermediates for preparing anti-HIV Agents | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340379-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS | SAMHD1, DHPS, LSS | BTN3A1 4464/4885TSHR 4779/4885RECQL 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.